PriceTargets.com logo

electroCore - ECOR Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$10.94 As of 11/15/2024 01:00 AM ET
▼ -2.66 (-19.56%)

This chart shows the closing price for ECOR by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New electroCore Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ECOR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ECOR

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 1 analysts offering 12 month price targets for electroCore in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $10.94.

This chart shows the closing price for ECOR for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 1 investment analysts is to buy stock in electroCore. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/27/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/25/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/23/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/21/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/21/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/19/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/18/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/17/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
3/14/2024HC WainwrightReiterated RatingBuy ➝ Buy
8/10/2023HC WainwrightReiterated RatingBuy ➝ Buy
5/4/2023HC WainwrightBoost Target$8.00 ➝ $10.00
3/9/2023HC WainwrightReiterated RatingBuy
1/13/2023Brookline Capital AcquisitionInitiated CoverageBuy
1/12/2023Brookline Capital ManagementReiterated RatingBuy
10/6/2022Berenberg BankLower TargetBuyGBX 5,850 ➝ GBX 4,950
3/11/2022Maxim GroupInitiated CoverageBuy$22.50
1/19/2022HC WainwrightLower TargetBuy$45.00 ➝ $41.25
8/10/2021HC WainwrightReiterated RatingBuy$45.00
8/6/2021Maxim GroupReiterated RatingBuy$45.00
7/27/2021LADENBURG THALM/SH SHInitiated CoverageBuy$13.95
3/12/2021Maxim GroupReiterated RatingBuy$45.00
11/13/2020Maxim GroupReiterated RatingBuy$45.00
10/23/2020Brookline Capital ManagementInitiated CoverageBuy$75.00
9/30/2020Maxim GroupInitiated CoverageBuy$45.00
8/14/2020HC WainwrightBoost TargetBuy$37.50 ➝ $45.00
8/14/2020BTIG ResearchUpgradeNeutral ➝ Buy$52.50
7/15/2020HC WainwrightReiterated RatingBuy$22.50 ➝ $37.50
5/19/2020Noble FinancialReiterated RatingBuy$60.00
5/15/2020HC WainwrightReiterated RatingBuy$22.50
5/14/2020BTIG ResearchReiterated RatingHold
4/17/2020BTIG ResearchReiterated RatingHold
3/25/2020Noble FinancialReiterated RatingBuy$60.00
3/24/2020Cantor FitzgeraldLower TargetNeutral$60.00 ➝ $30.00
3/24/2020HC WainwrightLower TargetBuy$30.00 ➝ $22.50
3/10/2020HC WainwrightInitiated CoverageBuy$30.00
(Data available from 11/17/2019 forward)

News Sentiment Rating

0.63 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/21/2024
  • 4 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/21/2024
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/20/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/20/2024
  • 2 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/19/2024
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/18/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
10/18/2024
  • 7 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/17/2024

Current Sentiment

  • 7 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

electroCore logo
electroCore, Inc., a commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally. The company is developing gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania. It also develops Truvaga for the support of general health and wellbeing; and TAC-STIM for human performance. In addition, the company offers gammacore Sapphire, a portable, reusable, rechargeable, and reloadable prescription medical device for various primary headache conditions. electroCore, Inc. was incorporated in 2005 and is headquartered in Rockaway, New Jersey.
Read More

Today's Range

Now: $10.94
Low: $10.76
High: $13.93

50 Day Range

MA: $8.89
Low: $5.85
High: $13.60

52 Week Range

Now: $10.94
Low: $5.02
High: $14.20

Volume

199,197 shs

Average Volume

26,853 shs

Market Capitalization

$70.56 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.56

Frequently Asked Questions

What sell-side analysts currently cover shares of electroCore?

The following Wall Street research analysts have issued research reports on electroCore in the last twelve months: HC Wainwright.
View the latest analyst ratings for ECOR.

What is the current price target for electroCore?

0 Wall Street analysts have set twelve-month price targets for electroCore in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for electroCore in the next year.
View the latest price targets for ECOR.

What is the current consensus analyst rating for electroCore?

electroCore currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ECOR will outperform the market and that investors should add to their positions of electroCore.
View the latest ratings for ECOR.

What other companies compete with electroCore?

Other companies that are similar to electroCore include Rockwell Medical, IRIDEX, Nuwellis, ClearPoint Neuro and Sanara MedTech. Learn More about companies similar to electroCore.

How do I contact electroCore's investor relations team?

electroCore's physical mailing address is 150 ALLEN ROAD SUITE 201, BASKING RIDGE NJ, 07920. The company's listed phone number is (973) 290-0097 and its investor relations email address is [email protected]. The official website for electroCore is www.electrocore.com. Learn More about contacing electroCore investor relations.